Abstract:BackgroundThe discovery of novel anticancer drugs is critical for the pharmaceutical research and development, and patient treatment. Repurposing existing drugs that may have unanticipated effects as potential candidates is one way to meet this important goal. Systematic investigation of efficient anticancer drugs could provide valuable insights into trends in the discovery of anticancer drugs, which may contribute to the systematic discovery of new anticancer drugs.ResultsIn this study, we collected and analyzed 150 anticancer drugs approved by the US Food and Drug Administration (FDA). Based on drug mechanism of action, these agents are divided into two groups: 61 cytotoxic-based drugs and 89 target-based drugs. We found that in the recent years, the proportion of targeted agents tended to be increasing, and the targeted drugs tended to be delivered as signal drugs. For 89 target-based drugs, we collected 102 effect-mediating drug targets in the human genome and found that most targets located on the plasma membrane and most of them belonged to the enzyme, especially tyrosine kinase. From above 150 drugs, we built a drug-cancer network, which contained 183 nodes (150 drugs and 33 cancer types) and 248 drug-cancer associations. The network indicated that the cytotoxic drugs tended to be used to treat more cancer types than targeted drugs. From 89 targeted drugs, we built a cancer-drug-target network, which contained 214 nodes (23 cancer types, 89 drugs, and 102 targets) and 313 edges (118 drug-cancer associations and 195 drug-target associations). Starting from the network, we discovered 133 novel drug-cancer associations among 52 drugs and 16 cancer types by applying the common target-based approach. Most novel drug-cancer associations (116, 87%) are supported by at least one clinical trial study.ConclusionsIn this study, we provided a comprehensive data source, including anticancer drugs and their targets and performed a detailed analysis in term of historical tendency and networks. Its application to identify novel drug-cancer associations demonstrated that the data collected in this study is promising to serve as a fundamental for anticancer drug repurposing and development.

The Compatibility of Anti-cancer Drugs and Drug Safety

Safe Medication Use Based on Knowledge of Information about Contraindications Concerning Cross Allergy and Comprehensive Clinical Intervention

Research progress in toxic effects of antitumor drugs based on drug transporter

Research progress of compatibility between antitumor drugs and infusion packaging materials

Prevention and Treatment Adverse Drug Reactions of Antitumor Medicines

Prevention and Management of Common ADRs Induced by Antitumor Drugs

Drug Combination in Clinical Cancer Treatments

The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent

A systematic analysis of FDA-approved anticancer drugs

Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study.

Combination of Chinese and Western Medicine to Prevent and Reverse Resistance of Cancer Cells to Anticancer Drugs

Efficacy-oriented compatibility for component-based Chinese medicine

Clinical analysis of 1946 cases of adverse drug reactions associated with chemotherapy in cancer patients

Current advances of anticancer drugs based on solubilization technology

[Compatibility for Toxicity Attenuation of Toxic Traditional Chinese Medicine: a Review and Strategies].

Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy

Clinical Evaluation on Platinum Anticancer Drugs

Clinical Evaluation and Rational Use of Anti-cold Drugs

Notice for Western Medicine Physicians in Clinical Use of Chinese Patent Drugs

Toxic Chinese Medicines for Cancer

Managing Drug Interactions With Oral Anticancer Treatments